Transmitted Antiretroviral Drug Resistance in the Men Who Have Sex with Men HIV Patient Cohort, Beijing, China, 2008-2011

被引:15
作者
Dai, Lili [1 ]
Li, Ning [1 ]
Wei, Feili [1 ]
Li, Jingyun [2 ]
Liu, Yongjian [2 ]
Xia, Wei [1 ]
Zhang, Tong [1 ]
Guo, Caiping [1 ]
Wang, Wen [1 ]
Schwartz, Stanley A. [3 ]
Mahajan, Supriya D. [3 ]
Hsiao, Chiu-Bin [4 ]
Wu, Hao [1 ]
机构
[1] Capital Med Univ, Beijing Youan Hosp, Ctr Infect Dis, Beijing 100069, Peoples R China
[2] Acad Mil Med Sci, Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China
[3] SUNY Buffalo, Dept Med, Div Allergy Immunol & Rheumatol, Buffalo, NY 14260 USA
[4] Allegheny Gen Hosp, Dept Med, Div Infect Dis, Pittsburgh, PA 15212 USA
关键词
PREVALENCE; MUTATIONS; EPIDEMIC; PROVINCE;
D O I
10.1089/vim.2014.0025
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Transmitted drug resistance (TDR) is an ongoing public health problem in HIV disease treatment. However, little is known about TDR among men who have sex with men (MSM) patients in China. In addition, TDR prevalence among patients with acute HIV infection (AHI) or early HIV infection (EHI) was believed higher than that of patients with chronic HIV infection (CHI), but as AHI is typically either unidentified or crudely defined in large populations, very few direct comparisons have been made. We did a retrospective analysis of TDR in 536 antiretroviral-naive MSM patients from our immunodeficiency clinics at You'an Hospital, Capital Medical University (CMU), in Beijing, China, 2008-2011. The cohort included 266 patients with AHI/EHI and 270 patients with CHI. We analyzed the subtype, estimated the TDR prevalence, and characterized the model of TDR and the predicted drug sensitivity. Additionally, we made a comparison of TDR between the patients with AHI/EHI and patients with CHI. Our results indicated that among the 536 patients, HIV-1 subtype CRF01_AE accounted for 52.1%, subtype B accounted for 24.8%, CRF07_BC/ CRF08_BC accounted for 21.6% (116/536), and 1.3% were denoted as unique recombinant forms (URFs). A total of 7.8% patients had one or more transmitted HIV-1 drug resistance mutations, representing 6.2% for PI-related mutations, 0.9% for NRTI-related mutations, and 1.7% for NNRTI-related mutations. Although patients with AHI/EHI had a higher TDR prevalence as compared to that of patients with CHI, the difference was not statistically significant. There was no significant difference in TDR model and predicted drug susceptibility between the two groups of patients either. This study provides important strategic information for public health planning by healthcare officials in China and warrants a comprehensive study with larger patient cohorts from various healthcare centers within China.
引用
收藏
页码:392 / 397
页数:6
相关论文
共 19 条
[1]   The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART) [J].
Bansi, Loveleen ;
Geretti, Anna Maria ;
Dunn, David ;
Hill, Teresa ;
Green, Hannah ;
Fearnhill, Esther ;
Gazzard, Brian ;
Nelson, Mark ;
Porter, Kholoud ;
Phillips, Andrew ;
Sabin, Caroline .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 53 (05) :633-639
[2]  
Beijing National Center for AZOS/STD Control and Prevention Chinese Center for Disease Control and Prevention, 2005, 2005 UPD HIV AIDS EP
[3]   Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update [J].
Bennett, Diane E. ;
Camacho, Ricardo J. ;
Otelea, Dan ;
Kuritzkes, Daniel R. ;
Fleury, Herve ;
Kiuchi, Mark ;
Heneine, Walid ;
Kantor, Rami ;
Jordan, Michael R. ;
Schapiro, Jonathan M. ;
Vandamme, Anne-Mieke ;
Sandstrom, Paul ;
Boucher, Charles A. B. ;
van de Vijver, David ;
Rhee, Soo-Yon ;
Liu, Tommy F. ;
Pillay, Deenan ;
Shafer, Robert W. .
PLOS ONE, 2009, 4 (03)
[4]  
Dai L, 2013, J ANTIVIR ANTIRETROV, V6, P13
[5]  
Frentz D, 2012, AIDS REV, V14, P17
[6]   Precise Determination of Time to Reach Viral Load Set Point After Acute HIV-1 Infection [J].
Huang, Xiaojie ;
Chen, Hui ;
Li, Wei ;
Li, Haiying ;
Jin, Xia ;
Perelson, Alan S. ;
Fox, Zoe ;
Zhang, Tong ;
Xu, Xiaoning ;
Wu, Hao .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 61 (04) :448-454
[7]  
Hurt CB, 2009, ANTIVIR THER, V14, P673
[8]   Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes [J].
Jain, Vivek ;
Sucupira, Maria C. ;
Bacchetti, Peter ;
Hartogensis, Wendy ;
Diaz, Ricardo S. ;
Kallas, Esper G. ;
Janini, Luiz M. ;
Liegler, Teri ;
Pilcher, Christopher D. ;
Grant, Robert M. ;
Cortes, Rodrigo ;
Deeks, Steven G. ;
Hecht, Frederick M. .
JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (08) :1174-1181
[9]   Transmitted Drug Resistance in Persons with Acute/Early HIV-1 in San Francisco, 2002-2009 [J].
Jain, Vivek ;
Liegler, Teri ;
Vittinghoff, Eric ;
Hartogensis, Wendy ;
Bacchetti, Peter ;
Poole, Lauren ;
Loeb, Lisa ;
Pilcher, Christopher D. ;
Grant, Robert M. ;
Deeks, Steven G. ;
Hecht, Frederick M. .
PLOS ONE, 2010, 5 (12) :1-4
[10]   HIV rebounds from latently infected cells, rather than from continuing low-level replication [J].
Joos, Beda ;
Fischer, Marek ;
Kuster, Herbert ;
Pillai, Satish K. ;
Wong, Joseph K. ;
Boeni, Juerg ;
Hirschel, Bernard ;
Weber, Rainer ;
Trkola, Alexandra ;
Guenthard, Huldrych F. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (43) :16725-16730